

CLAIMS

1. An adenoviral vector comprising a nucleic acid sequence encoding a hexon polypeptide comprising a hexon hypervariable regions-encompassing polypeptide comprising an amino acid sequence selected from SEQ ID NO: 1 or SEQ ID NO:2.
2. The adenoviral vector of claim 1, wherein the hexon polypeptide sequence comprises SEQ ID NO:3 or SEQ ID NO:4.
3. The adenoviral vector of claim 1 or claim 2, wherein the adenoviral vector further comprises an E1 deletion.
4. The adenoviral vector of any one of claims 1-3, wherein the adenoviral vector further comprises an E3 deletion.
5. The adenoviral vector of any one of claims 1-4, wherein the adenoviral vector further comprises a human adenovirus-5 (HAdV-5) E4 orf6.
6. The adenoviral vector of any one of claims 1-5, wherein the adenoviral vector comprises a nucleic acid sequence selected from SEQ ID NO: 5 or SEQ ID NO:6.
7. The adenoviral vector of any one of claims 1-6, wherein the adenoviral vector further comprises at least one transgene.
8. The adenoviral vector of any one of claims 1-7, wherein the transgene is located at the E1 deletion, at the E3 deletion, and/or adjacent to the right inverted terminal repeat (rITR).
9. The adenoviral vector of any one of claims 1-8, wherein the adenoviral vector comprises one or more nucleic acid sequences from human adenovirus-26 (Ad26).
10. A recombinant cell comprising the adenoviral vector of any one of claims 1-9.
11. A method of producing an adenoviral vector, comprising:
 - (a) growing the recombinant cell of claim 10 under conditions for production of the adenoviral vector; and
 - (b) isolating the adenoviral vector from the recombinant cell.
12. An immunogenic composition comprising the adenoviral vector of any one of claims 1-9 and a pharmaceutically acceptable carrier.
13. An immunogenic composition of claim 12 for use in inducing an immune response in a subject in need thereof.
14. A method of producing an immunogenic composition, the method comprising combining an adenoviral vector according to any one of claims 1-9 with a pharmaceutically acceptable carrier.